Ivan Tornos was appointed President and Chief Executive Officer and a member of the Board of Directors of Zimmer Biomet in August 2023. Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed as Chief Operating Officer in March 2021 with responsibility for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In this role, he had oversight of the Americas and the Europe, Middle East and Africa (EMEA) regions.
Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Prior to that, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. Before that, Mr. Tornos served as International Vice President, Business Development and Strategy with Baxter International Inc. and prior to that, he spent over a decade in leadership assignments around the globe with Johnson & Johnson.
Mr. Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business. Mr. Tornos currently serves as an independent member of the Board of Directors of global healthcare company PHC Holdings Corporation.
Mark Bezjak was appointed President, Americas in September 2023.
Mr. Bezjak joined Zimmer Biomet in April of 2008 as Director of
Corporate Sales and has held roles of increasing importance with the
Company, most recently serving as the President of North America,
As President, Americas he oversees all commercial, downstream
marketing and distribution activities in North America and Latin
Prior to his work at Zimmer Biomet, Mr. Bezjak held multiple roles
with Teleflex Medical and Michelin Tire Company.
He holds a Bachelor of Science in Marketing from Virginia Tech and an MBA in Strategic Leadership from the University of Richmond.
Rachel Ellingson was appointed Senior Vice President and Chief Strategy Officer in April 2018.
Prior to joining the Company, Ms. Ellingson served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical.
Before joining St. Jude Medical, she served as Vice President, Business Development and Investor Relations at AGA Medical Corporation. Previously, she served in a number of leadership roles in investment banking firms, including Bank of America and Cowen & Company. She has served as a member of the board of directors of Biolife Solutions, Inc. since April 2021.
Ms. Ellingson holds a Bachelor of Arts degree from the University of Rhode Island and an MBA in Finance from the University of Connecticut.
Dr. Nitin Goyal joined Zimmer Biomet in June 2021 in the newly created role of Chief Science, Technology and Innovation Officer. He was appointed to the Company’s Executive Leadership Team in September 2023. In his role, he oversees all global innovation, medical education, clinical affairs, and reimbursement strategy, reporting to President and CEO Ivan Tornos.
Dr. Goyal is a practicing adult hip and knee reconstruction surgeon. Prior to joining Zimmer Biomet, he also served as Chief Medical Officer and Senior Vice President of Innovation and Digital Care Delivery at Rally Health, part of the Optum business of UnitedHealth Group. Dr. Goyal is the Founder and CEO of Pulse Platform as well as Surgical Creations, leading both companies from inception to acquisition.
He received his Bachelor's degree from Penn State University, his Medical degree from the Jefferson Medical College and completed his residency in Orthopedic Surgery and fellowship in Adult Reconstruction at the Rothman Institute and Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.
Brian Hatcher was appointed President, CMFT, Trauma and Foot & Ankle in November 2021. He was appointed to the Company’s Executive Leadership Team in November 2023. In his role, he is responsible for the global strategy, portfolio and commercial execution of these businesses.
Mr. Hatcher joined the Company (then Biomet) in 2010 as the Director of Research and held rolls of progressing responsibility within CMFT. Prior to joining Biomet, he served in a variety of roles with Medtronic.
Mr. Hatcher holds a Bachelor of Science in Chemistry and a PhD in Biomedical Engineering, both from the University of Florida.
David Kunz was appointed Senior Vice President, Global Quality and Regulatory Affairs in May 2017. He is responsible for providing strategic and operational direction to achieve Quality and Regulatory Excellence across the organization and he chairs the Company’s Quality Excellence Steering Committee.
Mr. Kunz joined the Company (then Zimmer) in 2011 as Vice President, Regulatory Affairs and Quality Assurance for the Spine division. He was appointed Senior Vice President, Global Quality, Clinical and Regulatory Affairs in April 2016. Prior to joining Zimmer, he served as Vice President, Quality Assurance of Ecolab, where he led a supply chain network including nine chemical plants and two equipment plants.
Previously, he spent 13 years at Guidant/Boston Scientific Corporation in a variety of leadership positions, most recently as the Director of Supplier Quality Assurance for the CRV Division. He began his career at the Naval Nuclear Propulsion Program Headquarters as a mechanical engineer. Mr. Kunz holds a Bachelor of Science and an MBA from the University of Minnesota. He is a certified Nuclear Engineer and previously was a certified Licensed Professional Mechanical Engineer.
Jim Lancaster was appointed President, Recon in 2019 and Global Headquarters Executive Director in September 2023. He was appointed to the Company’s Executive Leadership Team in November 2023.
He is responsible for the Hip and Knee Reconstruction businesses, as well as fostering effective and efficient partnership with key stakeholders in the greater Warsaw, Indiana community.
Mr. Lancaster joined the Company (then Biomet) in 2007 as the Senior Director of Extremity and Knee in R&D. Previously, he spent 15 years with DePuy Orthopedics in a variety of leadership positions.
Mr. Lancaster holds a Bachelor of Science in Mechanical Engineering from Valparaiso University and a Master of Science from the University of Leeds (Leeds, United Kingdom).
Angela Main was appointed Senior Vice President, Global Chief Compliance Officer and Associate General Counsel, Asia Pacific in June 2015. She is responsible for the provision of compliance advice and ethical solutions to the Zimmer Biomet organization, including developing, operating and monitoring the Company’s Compliance Program.
Ms. Main served as Vice President, Legal and Compliance, Asia Pacific for Zimmer Biomet from September 2010 to June 2015. Prior to joining the Company in 2010, she worked for Covidien in Singapore, Lloyds TSB Bank plc in London and Texas Instruments in its European and Asia Pacific regional offices.
She has extensive international legal and compliance experience in the healthcare, financial services and technology sectors.
Keri P. Mattox was appointed Senior Vice President, Chief Communications and Administration Officer in May 2022, responsible for strategically integrating, aligning and driving investor relations, communications and philanthropy functions and activities, as well as environmental, social and governance (ESG) initiatives. She joined Zimmer Biomet in January 2020 as Senior Vice President, Investor Relations and Chief Communications Officer.
Prior to joining Zimmer Biomet, Ms. Mattox served as Global Lead,
Integrated Corporate Communications at W2O Group (now Real Chemistry),
an international healthcare-focused marketing and communications firm.
There she was responsible for strategically shaping and expanding the
firm’s global corporate communications, investor relations, crisis
communications, M&A, board engagement and corporate social
responsibility/foundation capabilities and offering.
Prior to W2O, Ms. Mattox was Vice President, Corporate & Investor Relations at AmerisourceBergen, a healthcare company ranked #10 on the Fortune 500. She also held executive leadership team level positions at Endo International and Auxilium Pharmaceuticals and spent more than 10 years at communications agencies in leadership positions. Earlier in her career, Ms. Mattox was a reporter with Hearst Newspapers. She holds a B.A. from Boston University and an M.A. in Journalism from the University of Maryland.
Nnamdi Njoku joined Zimmer Biomet in March 2023 as the President, Surgical, Sports, Upper Extremities and Restorative Therapies. He was appointed to the Company’s Executive Leadership Team in November 2023.
In his role, he oversees the Surgical, Sports, Upper Extremities and Restorative Therapies businesses.
Prior to joining the Company, Mr. Njoku spent 18 years at Medtronic, where he served in a number of positions of increasing seniority, most recently as President of the Neuromodulation business.
He holds a Bachelor of Arts in Accounting from the University of St. Thomas and an MBA from Cornell University.
Chad Phipps was appointed Senior Vice President, General Counsel and Secretary in May 2007. He has global responsibility for the Company’s Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company’s Government Affairs activities.
Mr. Phipps joined the Company (then Zimmer) in September 2003. Prior to joining Zimmer, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.
Mr. Phipps holds a Bachelor of Arts, magna cum laude, from Rollins College and a J.D. from Villanova University School of Law.
Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer of Zimmer Biomet in May 2022.
Prior to joining Zimmer Biomet, Mr. Stellato was a member of Xylem Inc.’s finance leadership team, where he most recently served as Vice President Finance, Global Business Services. Prior to that, he served as Xylem’s Vice President, Controller and Chief Accounting Officer and as Vice President Finance, Financial Planning and Analysis.
Previously, Mr. Stellato spent eight years at ITT Corporation, where he held various roles of increasing responsibility in the finance organization, including General Auditor and Manager, Investor Relations. Mr. Stellato spent the early part of his career in public accounting with both Andersen and Ernst & Young. He holds a Bachelor of Science in Accountancy from Villanova University and an MBA from the Stern School of Business at New York University. He is also a Certified Public Accountant.
Zeeshan Tariq was appointed Chief Information Officer in July 2016.
Prior to joining the Company, Mr. Tariq spent 17 years at Medtronic, where he served in a number of positions of increasing responsibility, most recently as Vice President and Chief Information Officer, Cardiovascular Group.
Prior to joining Medtronic, he worked in the Management Consulting, Systems Consulting and Banking industries. Mr. Tariq holds a Bachelor of Business Administration in Finance, Economics and Management Information Systems from the University of Nebraska; a Master of Science in Software Engineering from the University of Minnesota; and an MBA from the Carlson School of Management.
Kenneth Tripp was appointed Senior Vice President, Global Operations and Logistics in April 2018.
Prior to joining the Company, Mr. Tripp served as Senior Vice President, Manufacturing at Cardinal Health. Prior to joining Cardinal Health, he served as the Vice President of Operations of the Patient Monitoring and Recovery business at Medtronic.
Mr. Tripp is retired from 25 years of service in the U.S. Navy and U.S. Navy Reserve. Mr. Tripp holds a Bachelor of Arts in History and an MBA in Strategies in Organizational Leadership from Ashford University.
Suketu Upadhyay was appointed Chief Financial Officer and Executive Vice President, Finance, Operations & Supply Chain in August 2023 and is responsible for the strategic oversight of the Company’s global finance, global Operations and Supply Chain functions. He joined Zimmer Biomet in 2019 as Executive Vice President and Chief Financial Officer.
Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations at Bristol-Myers Squibb Company from November 2016 until June 2019. Before joining Bristol-Myers Squibb, he served as Executive Vice President and Chief Financial Officer of Endo International plc from September 2013 to November 2016.
Prior to his tenure at Endo International, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton, Dickinson and Company (BD). Prior to his role as BD’s Interim Chief Financial Officer and Corporate Controller, Mr. Upadhyay was the Senior Vice President of Global Financial Planning and Analysis and also held the role of Vice President and Chief Financial Officer of BD’s international business. Before joining BD in 2010, Mr. Upadhyay held a number of leadership roles across AstraZeneca PLC and Johnson & Johnson. These roles included the Global Head of R&D Finance, Head of Commercial Finance, Plant Controller, and Director of Business Development Finance. His experience spans over 20 years in the health care industry in financial roles of increasing responsibility covering all major areas of a fully integrated life sciences business. In addition, his experience covers businesses of varying size and scale and at different points of maturity. Mr. Upadhyay spent the early part of his career in public accounting with KPMG, and earned his CPA designation* in 1996 and his CMA designation* in 2002. He holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University. Mr. Upadhyay has also served as a member of the board of directors of Vertex Pharmaceuticals Incorporated since May 2022.
Ms. Winkler joined Zimmer Biomet in February 2020 as Global Vice President of HR for the Global Business Group and was appointed as Chief Human Resources Officer in March 2021.
Prior to joining Zimmer Biomet, Ms. Winkler served as a Worldwide Vice President of Human Resources in the Cardinal Health Medical Segment where she was responsible for 10,000 employees in over 70 countries. Before that, she served as the Global Head of Human Resources for Finance and Procurement at Johnson & Johnson (J&J). In this role, Ms. Winkler was the HR leader for the Chief Financial Officer of J&J and a member of the CFO’s senior staff, responsible for 6,000 employees worldwide. During her tenure at J&J, she served on a number of Global Management Boards as the HR leader for integrated, commercial businesses as well as large scale global functions including the Corporate Office of Science and Technology, Research & Development and Corporate Affairs.
Ms. Winkler received a Master of Science in Human Resources Development from Barry University, a Bachelor of Arts in Communications from Florida Atlantic University and an Executive Leadership Coaching Certification from Georgetown University.
Mr. Sang Yi (Sang) was appointed Group President, for Asia Pacific of Zimmer Biomet effective 19 Mar 2021. He is a Member of Zimmer Biomet Senior Leadership Team and oversees the overall operations, sales, marketing and distribution of products and business development in the Asia Pacific region comprising China, Japan, India, Australia, New Zealand, Korea and Southeast Asia. He also oversees channel management and portfolio rationalization activities outside of the U.S.
Sang joined Zimmer Biomet in March 2013 and was appointed Asia President in Jun 2015. Prior to this, Sang was the Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia & New Zealand since 2005. In that role, Sang managed a US$480 million region and distinguished himself with stellar 23% year-on-year growth, making his region the fastest growing region within St Jude Medical. Previous to that, he worked for 10 years with Boston Scientific Corporation, progressing through the ranks from Sales and Marketing Manager in its Korea business, before rising to Korea Country Director and then to Vice President for North Asia.
Sang graduated from the University of South Florida with a Bachelor of Science degree in Electrical Engineering.
Wilfred van Zuilen was appointed Group President of Europe Middle East and Africa (EMEA) in September 2023. He joined Zimmer Biomet in June 2021 as President, EMEA. He is responsible for the marketing, sales and distribution of products, services, and solutions in the region, and oversees select global research and development projects.
Prior to joining Zimmer Biomet, Mr. van Zuilen served as Regional Vice President, North Western Europe (United Kingdom, Ireland, Nordics and Benelux) at Medtronic. Prior to that, he led Medtronic’s Restorative Therapies Group of businesses for EMEA and has also held regional leadership positions with Covidien, Novartis and Edwards Lifesciences.
Mr. van Zuilen holds a bachelor’s degree in Business Economics from Erasmus University in Rotterdam.